Coronavirus disease 2019 (COVID-19) pandemic raises potential challenges for the healthcare system across the globe. With delayed diagnosis, increased risk of contracting infection and minimal resources; renal transplantation is becoming difficult for vulnerable patients. Induction therapy and immunosuppressive regimen increases the risk of COVID-19 in patients who have undergone renal transplant. Strategic choice of induction immunosuppression regimen in transplant recipients is the key to ensure success and prompt recovery. To elaborate more on this topic, Novartis and Docplexus have organised a webinar on 31st August 2020, Monday, 7:30 pm.
Join the experts, Dr. Nassir Kamar and Dr. Bharat V. Shah (Chairperson) as they share their views on Choice Of Induction Immunosuppression In Kidney Transplant Recipients In The COVID Era. At the end of the webinar, speakers will answer questions…
